Abbreviations {#nomen0010}
=============

(DLCO)

:   Diffusion capacity for carbon monoxide

(ERT)

:   enzyme replacement therapy

(FEV1)

:   forced expiratory volume in 1 second

(FVC)

:   forced vital capacity

(GD1)

:   Gaucher disease type 1

(ILD)

:   interstitial lung disease

(MMF)

:   mycophenolate mofetil

(RVSP)

:   right ventricular systolic pressure

(PAH)

:   pulmonary arterial hypertension

(PH)

:   pulmonary hypertension

(VA-ECMO)

:   venoarterial extracorporeal membrane oxygenation

(VV-ECMO)

:   venovenous extracorporal membrane oxygenation

1. Introduction {#sec1}
===============

Gaucher disease is an autosomal recessive inherited disorder that is the most common lysosomal storage disease, affecting approximately 1/40,000 live births \[[@bib1]\]. The three variants of the disease are characterized by deficient activity of the lysosomal enzyme, glucocerebrosidase. This results in the accumulation of its substrate, glucosylceramide, in lysosomes of macrophages, predominately in the bone marrow, liver and spleen \[[@bib2]\]. Gaucher disease type 1 (GD1) is the most common variant, especially in patients of Ashkenazi Jewish descent \[[@bib3]\].

Pulmonary involvement in GD1 can be characterized by interstitial lung disease (ILD) and/or pulmonary hypertension (PH) \[[@bib1],[@bib4]\]. PH is present in up to 30% of untreated GD1 patients, and 7% of patients receiving enzyme replacement therapy (ERT) \[[@bib5]\]. The majority of PH in GD1 patients is seen in splenectomised, female patients, and most cases are responsive to treatment with ERT \[[@bib5],[@bib6]\]. The patient highlighted in this case was previously included in a series of GD1 patients with PH \[[@bib5]\].

Treatment of GD1 with end-stage pulmonary manifestations by lung transplantation has been reported in two previous cases. Ours is the first reported case of lung transplantation in a patient with GD1 for severe PH without pulmonary parenchymal involvement. We also analyze disease-specific concerns for transplant in these patients, including the risk of GD1 pulmonary disease recurrence, immunosuppression in splenectomised patients, and the risk of liver and bone involvement in GD1.

1.1. Case presentation {#sec1.1}
----------------------

Our patient was initially diagnosed with GD1 thirty-six years prior to transplant at age 14 when she presented with splenomegaly and thrombocytopenia. She was treated with a splenectomy, and the diagnosis of GD1 was confirmed with enzymology and genotyping (*N370S/F417V*). This genotyping also confirmed the absence of any pulmonary arterial hypertension (PAH)-related genes. She was then lost to follow-up, but re-presented in 2000 at age 33 with dyspnea and was found to have severe PH. Treatment with imiglucerase (Cerezyme, Sanofi Genzyme, 45U/kg IV q2weeks), IV epoprostenol (Flolan^®^, GSK Canada, 92ng/kg/min), and warfarin was initiated. This was followed by addition of bosentan (125 mg PO BID) in 2006, and sildenafil (25 mg PO TID) in 2008. Flolan^®^ was eventually transitioned to a thermostable formulation of IV epoprostenol (Caripul^®^, Actelion Pharmaceuticals Canada, 88ng/kg/min). She was also managed for her comorbidities of GD1-associated osteopenia and gastroesophageal reflux.

The patient was referred for evaluation for lung transplantation at age 34 in 2001. She did not require transplantation at that time as she initially had a dramatic clinical response to her PH therapy. After a period with stable cardiopulmonary hemodynamics, her functional status worsened, and she progressed to require 3L of oxygen continuously ([Fig. 1](#fig1){ref-type="fig"}). Although her right ventricular systolic pressure (RVSP) from transthoracic echocardiography remained relatively stable, her right ventricular systolic function deteriorated, and she developed paradoxical septal motion with bowing into her left ventricle. As a result of this progression, she was actively listed for lung transplantation in 2016.Fig. 1Right ventricular systolic pressure according to transthoracic echocardiography (mmHg) and 6-min walk distance (m) prior to lung transplant.Abbreviations: RVSP, right ventricular systolic pressure; 6-MWD, 6-min walk distance.Fig. 1

The patient\'s last pre-transplant forced vital capacity (FVC) was 1.90L (68% predicted), forced expiratory volume in 1 second (FEV1) 1.23L (52% predicted), and diffusion capacity for carbon monoxide (DLCO) 20.50mL/min/mmHg (107% predicted). Imaging demonstrated no evidence of interstitial lung disease. Her last right heart catheterization 3 months prior to transplant demonstrated a mean pulmonary artery pressure of 62 mmHg, a pulmonary vascular resistance of 20.4 Wood units (increased from 11.2 Woods units 41 months previously), and a Fick cardiac output of 2.4L/min (decreased from 5.0L/min 41months previously).

Following active listing for transplant, the patient had three admissions for right heart failure and volume overload requiring IV diuresis. Computed tomography pulmonary embolism protocol did not show any evidence of pulmonary embolus but showed new increased interstitial markings in the lung parenchyma consistent with congestive heart failure ([Fig. 2](#fig2){ref-type="fig"}). Her condition worsened in 2018 and she was admitted to the critical care unit for vasopressor and inotrope therapy for two weeks until an appropriate donor became available. Her lung allocation score at this time was 45.9. She underwent a bilateral sequential lung transplantation and during the procedure required venoarterial extracorporeal membrane oxygenation (VA-ECMO). There was a size discrepancy with a large donor and a small recipient, so the patient received a left upper lobar transplant and a right lung transplant with a wedge resection of a portion of consolidated donor right lower lobe. The procedure was complicated by significant bleeding requiring massive transfusions and return to the OR for hemostasis.Fig. 2High resolution computed tomography (HRCT) images pre-transplant. A. gross dilatation of the main pulmonary arteries associated with rapid peripheral tapering, consistent with pulmonary arterial hypertension, and no evident filling defects to indicate venous thromboembolism. B. Cardiomegaly with four chamber enlargement, dilatation of the right ventricle and flattening of the inter-ventricular septum. C. Increased interstitial lung markings consistent with pulmonary edema, but overall preserved pulmonary parenchyma.Fig. 2

The explanted lungs demonstrated severe pulmonary arterial hypertensive changes, including intimal proliferation, plexiform and angiomatoid lesions ([Fig. 3](#fig3){ref-type="fig"}). There was also patchy bronchiolitis and pneumonitis, potentially reflecting microaspiration, mild infection or drug reaction, but there was no evidence of interstitial fibrosis. The lungs did not demonstrate any pathognomonic features of Gaucher disease, such as filling of the alveolar spaces with Gaucher macrophages, accumulation of Gaucher cells in the alveolar septae and capillaries or perilymphatic infiltration of Gaucher cells. There was also no bone marrow emboli in the pulmonary capillaries, a finding that has rarely been described in patients with GD1 and PH \[[@bib7],[@bib8]\]. The explant pathology in our patient was typical for that seen in patients with WHO PH group 1 PAH.Fig. 3Pathological specimens from lung explants demonstrating features of pulmonary arterial hypertension. A. Low-power micrograph of a plexiform-dilation lesion. The arrow indicates the classical "glomeruloid-like" plexus of narrow slit-like channels lined by endothelium. The arrowheads indicate the post-stenotic dilation and angiomatoid lesions typifying plexogenic arteriopathy. Original magnification 40X. Movat pentachrome stain. B. Intra-lobular arteriole (arrow) showing severe concentric laminar intimal fibrosis (arrow). Note the tunica media of normal thickness. Movat pentachrome stain; original magnification 100x.Fig. 3

Her post-transplant course was complicated by prolonged support with initially veno-arterial (VA)- then venovenous-ECMO (VV-ECMO). After weaning from VV-ECMO, she required a prolonged period of ventilation, and as a result received a tracheostomy three weeks following her transplant. She was successfully decannulated three weeks later. As a result of hemorrhagic shock, the patient developed acute tubular necrosis, requiring renal replacement therapy.

Eight months post-transplant, the patient remains dialysis-dependent with oliguria. Her lung function continues to improve eight months post-transplant with an FVC of 1.80L (63% predicted) and FEV1 of 1.47L (62% predicted). Her restrictive physiology is thought to be related to the donor lung resections and post-transplant hemothoraces resulting in chronic pleural disease. Her follow-up transbronchial biopsies and bronchoalveolar lavage demonstrate no evidence of acute rejection or infection. She is currently being maintained on immunosuppression with MMF, tacrolimus and prednisone, while continuing her ERT with imiglucerase and anticoagulation with warfarin.

2. Discussion {#sec2}
=============

There have only been two previous reports of lung transplantation in patients with GD1 \[[@bib9],[@bib10]\]. The first was in a 10 year old GD1 patient with extensive ILD, previous bronchoalveolar lavage with evidence of Gaucher cells, and pulmonary hypertensive crisis \[[@bib10]\]. The second case was in a patient transplanted at age 49 for severe PH and fibrotic ILD \[[@bib9]\]. In both cases, the patients were female, had been treated with ERT, and had undergone splenectomy prior to developing end-stage pulmonary disease. Ours is the first case of a lung transplant in a GD1 patient with severe PH, but without significant pulmonary parenchymal disease.

Pulmonary vascular disease in GD1 is more common than previously recognized, affecting up to 30% of untreated patients and approximately 7% of patients treated with ERT \[[@bib5]\]. The PH seen in GD1 is typically mild-to-moderate in severity, but end-stage PH occurs in approximately 1% of patients with GD1(6). PH in GD1 has been classified into WHO Group 5, for unclear or multifactorial mechanisms \[[@bib11]\]. The classic pathophysiologic explanation for PH in GD1 is that Gaucher cells deposit in the pulmonary parenchyma and capillaries, thus obstructing blood flow \[[@bib8],[@bib12]\]. However, severe PH in GD1 has been described with little-to-no evidence of Gaucher cells within the lungs \[[@bib2],[@bib13]\]. The impact of long-term ERT on the presence of Gaucher cells in the lungs is unclear, although this treatment may explain the absence of these cells in the explants from our patient. Other proposed mechanisms of PH include plugging of pulmonary capillaries with bone marrow emboli \[[@bib7],[@bib8]\], post-splenectomy PH \[[@bib5]\], and PH via the hepatopulmonary syndrome in patients with GD1-associated liver disease \[[@bib6]\]. Analysis of *BMPR2* and *ALK1* coding regions did not disclose a role for these modifier genes in GD1 \[[@bib6]\].

Splenectomy has been shown to be a primary factor in the development of PH in GD1 \[[@bib5],[@bib6]\]. The proposed mechanism of PH following splenectomy is thought to relate to hypercoagulability from lack of splenic clearance of platelets and megakaryocytes. This results in deposition of megakaryocytes and macrophages within the pulmonary vasculature, leading to development of proximal thrombi (i.e. chronic thromboembolic pulmonary hypertension phenotype) or distal thrombi manifesting as a plexogenic arteriopathy (i.e. pulmonary arterial hypertension phenotype) \[[@bib5],[@bib14]\].

Asplenia is also an important post-transplant consideration. Asplenic solid organ transplant recipients are more likely to experience bacterial pneumonias post-transplant \[[@bib15]\]. However, these patients may be at a lower risk of antibody-mediated rejection (AMR). Splenectomy has previously been used as a salvage treatment for AMR in kidney transplantation \[[@bib16]\], and it has also been used to facilitate ABO-incompatible kidney transplants \[[@bib17]\]. No studies have evaluated the mortality impact of splenectomy in lung transplant recipients.

Although it has previously been mentioned as a theoretical concern \[[@bib9]\], the risk of recurrence of PH related to GD1 in transplanted lungs should be extremely low if the patient remains on ERT. Patients treated with ERT have a much lower likelihood of developing PH or other pulmonary manifestations than those without ERT \[[@bib5]\]. As evidenced in our patient, long term treatment with imiglucerase may completely eliminate the Gaucher cells in the lungs, although it will not alleviate the thrombogenic risk associated with splenectomy. Ongoing ERT post-transplant and should minimize any risk of post-transplant pulmonary and systemic complications of GD1.

3. Conclusions {#sec3}
==============

Our case, in conjunction with the two previous cases of lung transplantation in GD1, demonstrates the efficacy of this treatment for patients with end-stage pulmonary disease from this condition, although reported follow-up is limited. Given the success and availability of ERT that has reduced the need for splenectomy, end stage pulmonary disease in GD1 may become less frequent. Nonetheless, 7% of patients with GD1 may develop severe PH despite adequate ERT. This is most common in female, splenectomised patients. As long as ERT is continued in the post-transplant course, there is no reason to anticipate that these patients would have more complications than other lung transplant recipients. Furthermore, the PH in these patients is most consistent with pulmonary arterial hypertension, raising the question of whether this should be reclassified as WHO Group 1 rather than Group 5 PH.
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